Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengda Pharmaceuticals CoSZSE:301201 +2.26%75 EBITDA Margin % is 7.61% as of Mar. 2026, which is 78% below its 10-year median of 35.15. GuruFocus rates SZSE:301201 with a GF Score™ of 75/100 and a GF Value™ of ¥30.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Chengda Pharmaceuticals Co ranks worse than 75.65% on this metric.
Chengda Pharmaceuticals Co (SZSE:301201) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chengda Pharmaceuticals Co EBITDA Margin % Related Terms
Chengda Pharmaceuticals Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301201 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengda Pharmaceuticals Co (SZSE:301201) has a EBITDA Margin % of 7.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chengda Pharmaceuticals Co and its competitors. This is 78% below median its historical median of 35.15. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #727 out of 961 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is Chengda Pharmaceuticals Co's EBITDA Margin % too high?
Chengda Pharmaceuticals Co's current EBITDA Margin % of 7.61% is 78% below median its 10-year median of 35.15. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Chengda Pharmaceuticals Co's value of 7.61% is 39.1% below this industry median. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #727 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #727 out of 961 companies for EBITDA Margin %. This places Chengda Pharmaceuticals Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Chengda Pharmaceuticals Co's value of 7.61% is 39.1% below this benchmark. While the company's 10-year median is 35.15 vs. the industry median of 12.49, Chengda Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengda Pharmaceuticals Co's current EBITDA Margin % of 7.61% is 39.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chengda Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current EBITDA Margin % is 7.61%, which is 78% below median its own 10-year median of 35.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥37.94 — trading 24.6% above its estimated fair value. The current EBITDA Margin % is 7.61%, which is 78% below median its 10-year median of 35.15 and 39.1% below the Drug Manufacturers industry median of 12.49. Chengda Pharmaceuticals Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current EBITDA Margin % is 7.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥37.94 is trading 24.6% above its estimated GF Value™ of ¥30.45.
GuruFocus considers Chengda Pharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SZSE:301201:
EBITDA Margin %: 7.61% (78% below median its 10-year median of 35.15)
GF Value™: ¥30.45 vs. price of ¥37.94 (24.6% above fair value)
Industry Position: 39.1% below the Drug Manufacturers median (#727 of 961)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score
Get the complete analysis for SZSE:301201
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
